Get Premium to unlock powerful stock data
NAS:AMGN (USA)  
Amgen Inc logo

Amgen Inc

$ 245.37 +2.28 (+0.94%) 08:08 PM EST
On watch
P/E:
24.17
P/B:
143.07
Market Cap:
$ 131.08B
Enterprise V:
$ 160.17B
Volume:
4.52M
Avg Vol (2M):
3.57M
Also Trade In:
Volume:
4.52M
Market Cap $:
131.08B
PE Ratio:
24.17
Avg Vol (2-Month):
3.57M
Enterprise Value $:
160.17B
PB Ratio:
143.07
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Description
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Financials (Next Earnings Date:2022-08-03 Est.)

AMGN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:AMGN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 26,316
EPS (TTM) ($) 10.16
Beta 0.56
Volatility % 21.61
14-Day RSI 51.46
14-Day ATR ($) 5.223961
20-Day SMA ($) 244.121
12-1 Month Momentum % 4.54
52-Week Range ($) 198.64 - 258.45
Shares Outstanding (Mil) 534.2

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Amgen Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More